From β-catenin to ARM-repeat proteins in adrenocortical disorders

Hormone and Metabolic Research

Volumn 46, Issue 12, 2014, Pages 889-896

  Berthon, A ^a   Stratakis, C A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

adrenocortical tumor; APC; ARMC5; macronodular adrenal hyperplasia; catenin

Indexed keywords

APC PROTEIN; ARMADILLO DOMAIN PROTEIN; BETA CATENIN;

ADRENAL CORTEX; ADRENAL CORTEX TUMOR; ADRENAL DISEASE; ADRENAL GLAND; CARCINOGENESIS; CELL ADHESION; COLON POLYPOSIS; HOMEOSTASIS; HUMAN; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REVIEW; TANDEM REPEAT; ANIMAL; METABOLISM; PATHOLOGY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND DISEASES; ANIMALS; ARMADILLO DOMAIN PROTEINS; BETA CATENIN; CARCINOGENESIS; HUMANS;

EID: 84910133074     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0034-1389993     Document Type: Review

References (61)

1. Huber A. H., Nelson W. J., Weis W. I. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell: 1997; 90 871 882
2. Tewari R., Bailes E., Bunting K. A., Coates J. C. Armadillo-repeat protein functions: questions for little creatures. Trends Cell Biol: 2010; 20 470 481
3. Chain P. S., Grafham D. V., Fulton R. S., Fitzgerald M. G., Hostetler J., Muzny D., Ali J., Birren B., Bruce D. C., Buhay C., Cole J. R., Ding Y., Dugan S., Field D., Garrity G. M., Gibbs R., Graves T., Han C. S., Harrison S. H., Highlander S., Hugenholtz P., Khouri H. M., Kodira C. D., Kolker E., Kyrpides N. C., Lang D., Lapidus A., Malfatti S. A., Markowitz V., Metha T., Nelson K. E., Parkhill J., Pitluck S., Qin X., Read T. D., Schmutz J., Sozhamannan S., Sterk P., Strausberg R. L., Sutton G., Thomson N. R., Tiedje J. M., Weinstock G., Wollam A., Detter J. C. Genomics. Genome project standards in a new era of sequencing. Science: 2009; 326 236 237
4. Coates J. C. Armadillo repeat proteins: beyond the animal kingdom. Trends Cell Biol: 2003; 13 463 471
5. Valenta T., Hausmann G., Basler K. The many faces and functions of beta-catenin. EMBO J: 2012; 31 2714 2736
6. Clevers H., Nusse R. Wnt/beta-catenin signaling and disease. Cell: 2012; 149 1192 1205
7. Liu C., Li Y., Semenov M., Han C., Baeg G. H., Tan Y., Zhang Z., Lin X., He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell: 2002; 108 837 847
8. Aberle H., Bauer A., Stappert J., Kispert A., Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J: 1997; 16 3797 3804
9. Yang-Snyder J., Miller J. R., Brown J. D., Lai C. J., Moon R. T. A frizzled homolog functions in a vertebrate Wnt signaling pathway. Curr Biol: 1996; 6 1302 1306
10. Sugioka K., Mizumoto K., Sawa H. Wnt regulates spindle asymmetry to generate asymmetric nuclear beta-catenin in C. elegans. Cell: 2011; 146 942 954
11. Munemitsu S., Albert I., Souza B., Rubinfeld B., Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA: 1995; 92 3046 3050
12. Grumbach M. M., Biller B. M., Braunstein G. D., Campbell K. K., Carney J. A., Godley P. A., Harris E. L., Lee J. K., Oertel Y. C., Posner M. C., Schlechte J. A., Wieand H. S. Management of the clinically inapparent adrenal mass (incidentaloma). Ann Intern Med: 2003; 138 424 429
13. Boland G. W., Blake M. A., Hahn P. F., Mayo-Smith W. W. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology: 2008; 249 756 775
14. Latronico A. C., Chrousos G. P. Neoplasms of the adrenal cortex. Clinical and basic aspects. Cancer Treat Res: 1997; 89 217 237
15. McNicol A. M. Diagnostic and molecular aspects of adrenal cortical tumors. Seminars Diagnost Pathol: 2013; 30 197 206
16. Fagugli R. M., Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Inter J Hypertens: 2011; 2011 162804
17. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab: 2009; 23 245 259
18. Almeida M. Q., Stratakis C. A. Carney complex and other conditions associated with micronodular adrenal hyperplasias. Best Pract Res Clin Endocrinol Metab: 2010; 24 907 914
19. Luconi M., Mannelli M. Xenograft models for preclinical drug testing: implications for adrenocortical cancer. Mol Cell Endocrinol: 2012; 351 71 77
20. Gicquel C., Baudin E., Lebouc Y., Schlumberger M. Adrenocortical carcinoma. Ann Oncol: 1997; 8 423 427
21. Reibetanz J., Jurowich C., Erdogan I., Nies C., Rayes N., Dralle H., Behrend M., Allolio B., Fassnacht M. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg: 2012; 255 363 369
22. Haegel H., Larue L., Ohsugi M., Fedorov L., Herrenknecht K., Kemler R. Lack of beta-catenin affects mouse development at gastrulation. Development: 1995; 121 3529 3537
23. Kim A. C., Reuter A. L., Zubair M., Else T., Serecky K., Bingham N. C., Lavery G. G., Parker K. L., Hammer G. D. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development: 2008; 135 2593 2602
24. King P., Paul A., Laufer E. Shh signaling regulates adrenocortical development and identifies progenitors of steroidogenic lineages. Proc Natl Acad Sci USA: 2009; 106 21185 21190
25. Berthon A., Sahut-Barnola I., Lambert-Langlais S., de Joussineau C., Damon-Soubeyrand C., Louiset E., Taketo M. M., Tissier F., Bertherat J., Lefrancois-Martinez A. M., Martinez A., Val P. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Human Mol Genet: 2010; 19 1561 1576
26. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A. M., Rene-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M. C., Perret C., Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res: 2005; 65 7622 7627
27. Morin P. J., Sparks A. B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science: 1997; 275 1787 1790
28. Lepourcelet M., Chen Y. N., France D. S., Wang H., Crews P., Petersen F., Bruseo C., Wood A. W., Shivdasani R. A. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell: 2004; 5 91 102
29. Doghman M., Cazareth J., Lalli E. The T cell factor/beta-catenin antagonist PKF115-584 inhibits proliferation of adrenocortical carcinoma cells. J Clin Endocrinol Metab: 2008; 93 3222 3225
30. Gaujoux S., Hantel C., Launay P., Bonnet S., Perlemoine K., Lefevre L., Guillaud-Bataille M., Beuschlein F., Tissier F., Bertherat J., Rizk-Rabin M., Ragazzon B. Silencing mutated beta-catenin inhibits cell proliferation and stimulates apoptosis in the adrenocortical cancer cell line H295R. PloS One: 2013; 8 e55743
31. Bonnet S., Gaujoux S., Launay P., Baudry C., Chokri I., Ragazzon B., Libe R., Rene-Corail F., Audebourg A., Vacher-Lavenu M. C., Groussin L., Bertagna X., Dousset B., Bertherat J., Tissier F. Wnt/beta-catenin pathway activation in adrenocortical adenomas is frequently due to somatic CTNNB1-activating mutations, which are associated with larger and nonsecreting tumors: a study in cortisol-secreting and -nonsecreting tumors. J Clin Endocrinol Metab: 2011; 96 E419 E426
32. Ragazzon B., Libe R., Gaujoux S., Assie G., Fratticci A., Launay P., Clauser E., Bertagna X., Tissier F., de Reynies A., Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res: 2010; 70 8276 8281
33. Gaujoux S., Grabar S., Fassnacht M., Ragazzon B., Launay P., Libe R., Chokri I., Audebourg A., Royer B., Sbiera S., Vacher-Lavenu M. C., Dousset B., Bertagna X., Allolio B., Bertherat J., Tissier F. beta-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res: 2011; 17 328 336
34. Tadjine M., Lampron A., Ouadi L., Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol: 2008; 68 264 270
35. Stratakis C. A. Genetics of adrenocortical tumors: gatekeepers, landscapers and conductors in symphony. Trends Endocrinol Metab: 2003; 14 404 410
36. Stratakis C. A. Adrenal cancer in 2013: Time to individualize treatment for adrenocortical cancer? Nature Rev Endocrinol: 2014; 10 76 78
37. Tissier F. Classification of adrenal cortical tumors: what limits for the pathological approach? Best Pract Res Clin Endocrinol Metab: 2010; 24 877 885
38. Gaujoux S., Tissier F., Groussin L., Libe R., Ragazzon B., Launay P., Audebourg A., Dousset B., Bertagna X., Bertherat J. Wnt/beta-catenin and 3′,5′-cyclic adenosine 5′-monophosphate/protein kinase A signaling pathways alterations and somatic beta-catenin gene mutations in the progression of adrenocortical tumors. The Journal of clinical endocrinology and metabolism: 2008; 93 4135 4140
39. Boulkroun S., Samson-Couterie B., Golib-Dzib J. F., Amar L., Plouin P. F., Sibony M., Lefebvre H., Louiset E., Jeunemaitre X., Meatchi T., Benecke A., Lalli E., Zennaro M. C. Aldosterone-producing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology: 2011; 152 4753 4763
40. Heikkila M., Peltoketo H., Leppaluoto J., Ilves M., Vuolteenaho O., Vainio S. Wnt-4 deficiency alters mouse adrenal cortex function, reducing aldosterone production. Endocrinology: 2002; 143 4358 4365
41. Berthon A., Drelon C., Ragazzon B., Boulkroun S., Tissier F., Amar L., Samson-Couterie B., Zennaro M. C., Plouin P. F., Skah S., Plateroti M., Lefebvre H., Sahut-Barnola I., Batisse-Lignier M., Assie G., Lefrancois-Martinez A. M., Bertherat J., Martinez A., Val P. WNT/beta-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Human Mol Genet: 2014; 23 889 905
42. Fernandes-Rosa F. L., Williams T. A., Riester A., Steichen O., Beuschlein F., Boulkroun S., Strom T. M., Monticone S., Amar L., Meatchi T., Mantero F., Cicala M. V., Quinkler M., Fallo F., Allolio B., Bernini G., Maccario M., Giacchetti G., Jeunemaitre X., Mulatero P., Reincke M., Zennaro M. C. Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma. Hypertension: 2014; 64 354 361
43. Seccia T. M., Fassina A., Nussdorfer G. G., Pessina A. C., Rossi G. P. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Rel Cancer: 2005; 12 149 159
44. Berthon A., Martinez A., Bertherat J., Val P. Wnt/beta-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol: 2012; 351 87 95
45. Barzon L., Masi G., Fincati K., Pacenti M., Pezzi V., Altavilla G., Fallo F., Palu G. Shift from Conn's syndrome to Cushing's syndrome in a recurrent adrenocortical carcinoma. Eur J Endocrinol: 2005; 153 629 636
46. Abma E. M., Kluin P. M., Dullaart R. P. Malignant aldosterone-producing adrenal tumour: reoccurrence with glucocorticoid excess without hyperaldosteronism. Netherl J Med: 2008; 66 252 255
47. Mussig K., Wehrmann M., Horger M., Maser-Gluth C., Haring H. U., Overkamp D. Adrenocortical carcinoma producing 11-deoxycorticosterone: a rare cause of mineralocorticoid hypertension. J Endocrinol Invest: 2005; 28 61 65
48. Buchert M., Athineos D., Abud H. E., Burke Z. D., Faux M. C., Samuel M. S., Jarnicki A. G., Winbanks C. E., Newton I. P., Meniel V. S., Suzuki H., Stacker S. A., Nathke I. S., Tosh D., Huelsken J., Clarke A. R., Heath J. K., Sansom O. J., Ernst M. Genetic dissection of differential signaling threshold requirements for the Wnt/beta-catenin pathway in vivo. PLoS Genet: 2010; 6 e1000816
49. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Molecular and cellular endocrinology: 2012; 351 66 70
50. Hsiao H. P., Kirschner L. S., Bourdeau I., Keil M. F., Boikos S. A., Verma S., Robinson-White A. J., Nesterova M., Lacroix A., Stratakis C. A. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab: 2009; 94 2930 2937
51. Smith T. G., Clark S. K., Katz D. E., Reznek R. H., Phillips R. K. Adrenal masses are associated with familial adenomatous polyposis. Dis Colon Rectum: 2000; 43 1739 1742
52. Marchesa P., Fazio V. W., Church J. M., McGannon E. Adrenal masses in patients with familial adenomatous polyposis. Dis Colon Rectum: 1997; 40 1023 1028
53. Gaujoux S., Pinson S., Gimenez-Roqueplo A. P., Amar L., Ragazzon B., Launay P., Meatchi T., Libe R., Bertagna X., Audebourg A., Zucman-Rossi J., Tissier F., Bertherat J. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res: 2010; 16 5133 5141
54. Heaton J. H., Wood M. A., Kim A. C., Lima L. O., Barlaskar F. M., Almeida M. Q., Fragoso M. C., Kuick R., Lerario A. M., Simon D. P., Soares I. C., Starnes E., Thomas D. G., Latronico A. C., Giordano T. J., Hammer G. D. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and beta-catenin. Am J Pathol: 2012; 181 1017 1033
55. Assie G., Libe R., Espiard S., Rizk-Rabin M., Guimier A., Luscap W., Barreau O., Lefevre L., Sibony M., Guignat L., Rodriguez S., Perlemoine K., Rene-Corail F., Letourneur F., Trabulsi B., Poussier A., Chabbert-Buffet N., Borson-Chazot F., Groussin L., Bertagna X., Stratakis C. A., Ragazzon B., Bertherat J. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome. N Engl J Med: 2013; 369 2105 2114
56. Knudson A. G. Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA: 1971; 68 820 823
57. Faucz F. R., Zilbermint M., Lodish M. B., Szarek E., Trivellin G., Sinaii N., Berthon A., Libe R., Assie G., Espiard S., Drougat L., Ragazzon B., Bertherat J., Stratakis C. A. Macronodular Adrenal Hyperplasia due to Mutations in an Armadillo Repeat Containing 5 (ARMC5) Gene: A Clinical and Genetic Investigation. J Clin Endocrinol Metab: 2014; 99 E1113 E1119
58. Alencar G. A., Lerario A. M., Nishi M. Y., Mariani B. M., Almeida M. Q., Tremblay J., Hamet P., Bourdeau I., Zerbini M. C., Pereira M. A., Gomes G. C., De Souza Rocha M., Chambo J. L., Lacroix A., Mendonca B. B., Fragoso M. C. ARMC5 Mutations are a Frequent Cause of Primary Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab: 2014; jc20134237
59. Gagliardi L., Schreiber A. W., Hahn C. N., Feng J., Cranston T., Boon H., Hotu C., Oftedal B. E., Cutfield R., Adelson D. L., Braund W. J., Gordon R. D., Rees D. A., Grossman A. B., Torpy D. J., Scott H. S. Armc5 Mutations Are Common in Familial Bilateral Macronodular Adrenal Hyperplasia. J Clin Endocrinol Metab: 2014; jc20141265
60. Kelley L. A., Sternberg M. J. Protein structure prediction on the Web: a case study using the Phyre server. Nature Protocols: 2009; 4 363 371
61. Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C., Ferrin T. E. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem: 2004; 25 1605 1612